ADVERTISEMENT

Laurus Labs, Supriya Lifesciences, Divi’s Labs— DRChoksey's Top Stock Picks In Pharma Pack; Q1 Results Preview

Pharma Q1 Results Preview: Lupin is expected to return to double-digit growth with new launches scale up, adds DRChoksey

<div class="paragraphs"><p>As per Pharma rack data, during April 2025, the Indian pharmaceutical market grew by 7.8% YoY, led by improved price realization, modest new launches, and muted volume growth.</p><p> (Photo Source: <a href="https://unsplash.com/@lancereis?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Lance Reis</a> on <a href="https://unsplash.com/photos/a-close-up-of-a-bottle-of-pills-on-a-table-l5JPHAYkEmg?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>)</p></div>
As per Pharma rack data, during April 2025, the Indian pharmaceutical market grew by 7.8% YoY, led by improved price realization, modest new launches, and muted volume growth.

(Photo Source: Lance Reis on Unsplash)

Although the threat of US tariffs on Indian pharmaceutical imports has created uncertainty and market volatility, so far, the sector has been largely exempted, as it plays a critical role in the US healthcare. However, the risk lingers on companies specifically with higher US exposure. India and the US are engaged in negotiations, and the long-term outlook will depend on the evolution of trade policies and the ability of Indian pharm...
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit